17:55 , Aug 24, 2017 |  BC Innovations  |  Translation in Brief

The skinny on leishmaniasis

University of York scientists have shown skin, not just blood, is a major route by which Leishmania parasites spread from visceral leishmaniasis (VL) patients to the sand fly vector and back to a new host....
19:37 , Jul 3, 2017 |  BC Extra  |  Preclinical News

Paper names scaffold protein as target for infection

In a paper published in Cell Chemical Biology, researchers from the University of Würzburg showed that inhibition of the membrane scaffold protein Staphylococcus aureus flotillin reduced virulence. The authors suggested the target could be used...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Infectious disease INDICATION: Leishmaniasis In vitro and hamster studies identified aminopyrazole ureas that could help treat visceral leishmaniasis. Chemical synthesis and testing of aminopyrazole urea analogs in Leishmania infantum-infected mouse macrophages identified several compounds that inhibited growth...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Knight Therapeutics infectious news

Knight hired an investment bank to sell its neglected tropical disease Priority Review voucher. Knight received the voucher from FDA in March following the approval of leishmaniasis drug Impavido miltefosine under the agency’s...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Knight Therapeutics, Medicure cardiovascular news

Medicure hired Knight as an advisor to advance the company's U.S. specialty pharmaceutical business and "corporate development initiatives." Medicure has rights from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) to Aggrastat tirofiban...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Impavido miltefosine regulatory update

FDA approved an NDA for Impavido miltefosine from Knight Therapeutics to treat cutaneous, mucosal and visceral leishmaniasis. The agency said Impavido is the first drug approved for cutaneous or mucosal leishmaniasis. Knight said it could...
07:00 , May 30, 2000 |  BC Week In Review  |  Clinical News

Apra: Phase II

Among 28 evaluable patients in CTIC's ongoing 80-patient Phase II trial, 1 patient has had a partial response and 4 had stable disease. Side effects included hematuria and fatigue. Data were presented at the American...
07:00 , May 30, 2000 |  BC Week In Review  |  Clinical News

Apra: Phase II

Among 28 evaluable patients in CTIC’s ongoing 80-patient Phase II trial, 1 patient has had a partial response and 4 had stable disease. Side effects included hematuria and fatigue. Data were presented at the American...